The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes
Open accessAbstract
The effects of five antifungal drugs, fluconazole, itraconazole, micafungin, miconazole, and voriconazole, on cytochrome P450 (CYP) 2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, and CYP3A4-mediated nifedipine oxidation activities in human liver microsomes were compared. In addition, the effects of preincubation were estimated to investigate the mechanism-based inhibition. The IC50 value against tolbutamide hydroxylation was the lowest for miconazole (2.0 microM), followed by voriconazole (8.4 microM) and fluconazole (30.3 microM). Similarly, the IC50 value against S-mephenytoin 4'-hydroxylation was the lowest for miconazole (0.33 microM), followed by voriconazole (8.7 microM) and fluconazole (12.3 microM). On the other hand, micafungin at a concentration of 10 or 25 microM neither inhibited nor stimulated tolbutamide hydroxylation and S-mephenytoin 4'-hydroxylation, and the IC50 values for itraconazole against these were greater than 10 microM. These results suggest that miconazole is the strongest inhibitor of CYP2C9 and CYP2C19, followed by voriconazole and fluconazole, whereas micafungin would not cause clinically significant interactions with other drugs that are metabolized by CYP2C9 or CYP2C19 via the inhibition of metabolism. The IC50 value of voriconazole against nifedipine oxidation was comparable with that of fluconazole and micafungin and higher than that of itraconazole and miconazole. The stimulation of the inhibition of CYP2C9-, CYP2C19-, or CYP3A4-mediated reactions by 15-min preincubation was not observed for any of the antifungal drugs, suggesting that these drugs are not mechanism-based inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Molecular genetics of the P-450 superfamily
Gonzalez, F. J. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90006-n · Cited by 493
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
Guengerich, F. P. (1990) · Chemical Research in Toxicology · doi:10.1021/tx00016a015 · Cited by 279
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000315 · Cited by 276
Clinical Pharmacokinetics of Fluconazole
Debruyne, D., & Ryckelynck, J.-P. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324010-00002 · Cited by 255
Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives
Zhang, W., Ramamoorthy, Y., Kilicarslan, T., Nolte, H., Tyndale, R. F., & Sellers, E. M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.314 · Cited by 249
Characterization of human cytochrome P450 enzymes
Guengerich, F. P. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.2.1537465 · Cited by 227
Olkkola, K. T., Ahonen, J., & Neuvonen, P. J. (1996) · Anesthesia & Analgesia · doi:10.1097/00000539-199603000-00015 · Cited by 224
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04251.x · Cited by 218
Jeu, L., Piacenti, F. J., Lyakhovetskiy, A. G., & Fung, H. B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80126-1 · Cited by 213
Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes
Draper, A. J., Madan, A., & Parkinson, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9964 · Cited by 191
Hitchcock, C. A., Dickinson, K., Brown, S. B., Evans, E. G. V., & Adams, D. J. (1990) · Biochemical Journal · doi:10.1042/bj2660475 · Cited by 190
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black, D. J., Kunze, K. L., Wienkers, L. C., Gidal, B. E., Seaton, T. L., McDonnell, N. D., Evans, J. S., Bauwens, J. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07369-6 · Cited by 178
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients
Romero, A. J., Pogamp, P. L., Nilsson, L., & Wood, N. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121911 · Cited by 169
Pea, F., & Furlanut, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00004 · Cited by 165
Kunze, K. L., Wienkers, L. C., Thummel, K. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07368-4 · Cited by 161
Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li, S., Wang, J., Zhang, Q., Huang, M., & Xu, A. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335450 · Cited by 155
IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACT
Iwata, H., Tezuka, Y., Kadota, S., Hiratsuka, A., & Watabe, T. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000646 · Cited by 153
Voriconazole: A New Triazole Antifungal Agent
Pearson, M., Rogers, P. D., Cleary, J. D., & Chapman, S. W. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c261 · Cited by 148
Lin, H.-L., Kent, U. M., & Hollenberg, P. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.160 · Cited by 132
In vitro assessment of human cytochrome P450
Clarke, S. E. (1998) · Xenobiotica · doi:10.1080/004982598238877 · Cited by 127
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
Purkins, L., Wood, N., Ghahramani, P., Love, E. R., Eve, M. D., & Fielding, A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01997.x · Cited by 120
Effect of fluconazole on the disposition of phenytoin
Blum, R. A., Wilton, J. H., Hilligoss, D. M., Gardner, M., Henry, E. B., Harrison, N. J., & Schentag, J. J. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.49 · Cited by 120
Sakaeda, T., Iwaki, K., Kakumoto, M., Nishikawa, M., Niwa, T., Jin, J.-S., Nakamura, T., Nishiguchi, K., Okamura, N., & Okumura, K. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357056118 · Cited by 101
Self-citationAhonen, J., Olkkola, K. T., & Neuvonen, P. J. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050223 · Cited by 85
Huang, S. M., Lesko, L. J., & Williams, R. L. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922011764 · Cited by 67
Khan, K. K., He, Y., Correia, M. A., & Halpert, J. R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.9.985 · Cited by 58
Interaction between fluconazole and midazolam in intensive care patients
Ahonen, J., Olkkola, K. T., Takala, A., et al. (1999) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.1999.430504.x · Cited by 55
Niwa, T., Shiraga, T., Yamasaki, S., Ishibashi, K., Ohno, Y., & Kagayama, A. (2003) · Xenobiotica · doi:10.1080/0049825031000121617 · Cited by 39
Self-citationTassaneeyakul, W., Birkett, D., & Miners, J. O. (1998) · Xenobiotica · doi:10.1080/004982598239579 · Cited by 33
Fromtling, R. A. (2002) · Drugs of today · doi:10.1358/dot.2002.38.4.820091 · Cited by 30
Drug interactions of micafungin in vitro
Kaneko, H., Yamato, Y., Hashimoto, T., Ishii, I., Shiraga, T., Kawamura, A., Terakawa, M., & Kagayama, A. (2002) · Medical Entomology and Zoology · Cited by 12
Self-citation
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
Metadata
- Authors
- Niwa, T., Shiraga, T., & Takagi, A.
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2005
- Volume
- 28
- Issue
- 9
- Pages
- 1805-1808
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W1974054133
- Cited by
- 274
- References
- 35
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.